Literature DB >> 17442793

Multicenter laboratory evaluation of the MB/BacT Mycobacterium detection system and the BACTEC MGIT 960 system in comparison with the BACTEC 460TB system for susceptibility testing of Mycobacterium tuberculosis.

Montserrat Garrigó1, Lina Marcela Aragón, Fernando Alcaide, Sonia Borrell, Eugenia Cardeñosa, Juan José Galán, Julián Gonzalez-Martín, Nuria Martin-Casabona, Carmen Moreno, Margarita Salvado, Pere Coll.   

Abstract

In this multicenter study, the reliability of two nonradiometric, fully automated systems, the MB/BacT and BACTEC MGIT 960 systems, for testing the susceptibilities of 82 Mycobacterium tuberculosis strains to isoniazid, rifampin, ethambutol, and streptomycin was evaluated in comparison with the radiometric BACTEC 460TB system. The arbitration of discrepant results was done by the reanalysis of the strain, the determination of the MIC, and the molecular characterization of some resistance determinants. The overall level of agreement with BACTEC 460TB results was 96% with the MB/BacT test and 97.2% with the BACTEC MGIT 960 system. With both methods, the level of agreement with BACTEC 460TB results was 96.3% for isoniazid, 98.8% for rifampin, and 98.8% for ethambutol. The level of agreement for streptomycin was 90.2% with MB/BacT and 97.5% with BACTEC MGIT 960. Overall, there were 11 very major errors and 2 major errors with the MB/BacT method and 5 very major errors and 2 major errors with the BACTEC MGIT 960 system. In general, the MB/BacT and BACTEC MGIT 960 systems showed good performance for susceptibility testing with first-line antituberculosis drugs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17442793      PMCID: PMC1933104          DOI: 10.1128/JCM.02162-06

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  20 in total

1.  Comparison of susceptibility testing of Mycobacterium tuberculosis using the ESP culture system II with that using the BACTEC method.

Authors:  P Ruiz; F J Zerolo; M J Casal
Journal:  J Clin Microbiol       Date:  2000-12       Impact factor: 5.948

2.  Molecular genetic analysis of nucleotide polymorphisms associated with ethambutol resistance in human isolates of Mycobacterium tuberculosis.

Authors:  S V Ramaswamy; A G Amin; S Göksel; C E Stager; S J Dou; H El Sahly; S L Moghazeh; B N Kreiswirth; J M Musser
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

3.  Evaluation of MGIT 960-based antimicrobial testing and determination of critical concentrations of first- and second-line antimicrobial drugs with drug-resistant clinical strains of Mycobacterium tuberculosis.

Authors:  Annika Krüüner; Malcolm D Yates; Francis A Drobniewski
Journal:  J Clin Microbiol       Date:  2006-03       Impact factor: 5.948

4.  Evaluation of automated BACTEC MGIT 960 system for testing susceptibility of Mycobacterium tuberculosis to four major antituberculous drugs: comparison with the radiometric BACTEC 460TB method and the agar plate method of proportion.

Authors:  Enrico Tortoli; Marta Benedetti; Alessandra Fontanelli; M Tullia Simonetti
Journal:  J Clin Microbiol       Date:  2002-02       Impact factor: 5.948

5.  Susceptibility testing with the manual mycobacteria growth indicator tube (MGIT) and the MGIT 960 system provides rapid and reliable verification of multidrug-resistant tuberculosis.

Authors:  Kati Adjers-Koskela; Marja-Leena Katila
Journal:  J Clin Microbiol       Date:  2003-03       Impact factor: 5.948

6.  Evaluation of BACTEC Mycobacteria Growth Indicator Tube (MGIT 960) automated system for drug susceptibility testing of Mycobacterium tuberculosis.

Authors:  F Ardito; B Posteraro; M Sanguinetti; S Zanetti; G Fadda
Journal:  J Clin Microbiol       Date:  2001-12       Impact factor: 5.948

7.  Evaluation of the MB/BacT mycobacterium detection system for susceptibility testing of Mycobacterium tuberculosis.

Authors:  M S Díaz-Infantes; M J Ruiz-Serrano; L Martínez-Sánchez; A Ortega; E Bouza
Journal:  J Clin Microbiol       Date:  2000-05       Impact factor: 5.948

8.  Two liquid medium systems, mycobacteria growth indicator tube and MB redox tube, for Mycobacterium tuberculosis isolation from sputum specimens.

Authors:  L Heifets; T Linder; T Sanchez; D Spencer; J Brennan
Journal:  J Clin Microbiol       Date:  2000-03       Impact factor: 5.948

9.  Multicenter evaluation of fully automated BACTEC Mycobacteria Growth Indicator Tube 960 system for susceptibility testing of Mycobacterium tuberculosis.

Authors:  Pascale Bemer; Frantiska Palicova; Sabine Rüsch-Gerdes; Henri B Drugeon; Gaby E Pfyffer
Journal:  J Clin Microbiol       Date:  2002-01       Impact factor: 5.948

10.  Comparison of Mycobacterium tuberculosis susceptibility testing performed with BACTEC 460TB (Becton Dickinson) and MB/BacT (Organon Teknika) systems.

Authors:  E Tortoli; R Mattei; A Savarino; L Bartolini; J Beer
Journal:  Diagn Microbiol Infect Dis       Date:  2000-10       Impact factor: 2.803

View more
  24 in total

1.  Evaluation of the VersaTREK system compared to the Bactec MGIT 960 system for first-line drug susceptibility testing of Mycobacterium tuberculosis.

Authors:  M Espasa; M Salvadó; E Vicente; G Tudó; F Alcaide; P Coll; N Martin-Casabona; M Torra; D Fontanals; J González-Martín
Journal:  J Clin Microbiol       Date:  2011-11-30       Impact factor: 5.948

2.  Discordance between Xpert MTB/RIF assay and Bactec MGIT 960 Culture System for detection of rifampin-resistant Mycobacterium tuberculosis isolates in a country with a low tuberculosis (TB) incidence.

Authors:  Eiman Mokaddas; Suhail Ahmad; Hanaa S Eldeen; Noura Al-Mutairi
Journal:  J Clin Microbiol       Date:  2015-01-21       Impact factor: 5.948

3.  Mutations in the embC-embA intergenic region contribute to Mycobacterium tuberculosis resistance to ethambutol.

Authors:  Zhenling Cui; Yuanyuan Li; Song Cheng; Hua Yang; Junmei Lu; Zhongyi Hu; Baoxue Ge
Journal:  Antimicrob Agents Chemother       Date:  2014-09-02       Impact factor: 5.191

4.  Simple and rapid method to determine antimycobacterial potency of compounds by using autoluminescent Mycobacterium tuberculosis.

Authors:  Sreevalli Sharma; Ekaterina Gelman; Chandan Narayan; Deepa Bhattacharjee; Vijayashree Achar; Vaishali Humnabadkar; V Balasubramanian; Vasanthi Ramachandran; Neeraj Dhar; Neela Dinesh
Journal:  Antimicrob Agents Chemother       Date:  2014-07-21       Impact factor: 5.191

5.  Tubercular osteomyelitis of distal ulna presenting as epiphyseal injury.

Authors:  Ranjan Burnwal; Devdatta Suhas Neogi; Surendra Shukla D Ortho
Journal:  Maedica (Buchar)       Date:  2012-09

6.  Programmatic implementation of rapid DST for Mycobacterium tuberculosis in Peru.

Authors:  L Asencios; G Yale; M Yagui; N Quispe; A Taylor; J Blaya; C Contreras; P Cegielski; J Bayona; C Bonilla; S Shin
Journal:  Int J Tuberc Lung Dis       Date:  2008-07       Impact factor: 2.373

Review 7.  Tuberculosis in the developing world: recent advances in diagnosis with special consideration of extensively drug-resistant tuberculosis.

Authors:  Louis Grandjean; David A J Moore
Journal:  Curr Opin Infect Dis       Date:  2008-10       Impact factor: 4.915

8.  Performance of QuantaMatrix Microfluidic Agarose Channel system integrated with mycobacteria growth indicator tube liquid culture.

Authors:  Hyejin Kim; Sangyeop Lee; EunJi Jo; Suyeoun Kim; Haeun Kim; Eun-Geun Kim; Sunghoon Kwon; Soyoun Shin
Journal:  Appl Microbiol Biotechnol       Date:  2021-07-30       Impact factor: 4.813

Review 9.  Rapid diagnosis of drug resistance to fluoroquinolones, amikacin, capreomycin, kanamycin and ethambutol using genotype MTBDRsl assay: a meta-analysis.

Authors:  Yan Feng; Sijun Liu; Qungang Wang; Liang Wang; Shaowen Tang; Jianming Wang; Wei Lu
Journal:  PLoS One       Date:  2013-02-01       Impact factor: 3.240

10.  First evaluation after implementation of a quality control system for the second line drug susceptibility testing of Mycobacterium tuberculosis joint efforts in low and high incidence countries.

Authors:  Doris Hillemann; Sven Hoffner; Daniela Cirillo; Francis Drobniewski; Elvira Richter; Sabine Rüsch-Gerdes
Journal:  PLoS One       Date:  2013-10-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.